STOCKWATCH

Onesource Specialty Pharma to Subscribe to Equity Shares in Xbrane Biopharma AB, Sweden: Directed Issue of SEK 240 Million

Onesource Specialty Pharma Limited (the 'Company’) proposes to subscribe to equity shares of Xbrane Biopharma AB, Sweden. Xbrane Biopharma AB, headquartered in Solna, Sweden, is a biopharmaceutical company listed on Nasdaq Stockholm since 2019. The company develops biological drugs using its patented platform technology, which enables significantly lower production costs compared to conventional systems. Its portfolio includes biosimilar candidates targeting an estimated EUR 23 billion in combined peak annual sales of the respective reference products. Xbrane’s lead product, Xim/uci® (biosimilar ranibizumab), received market authorization in Europe and was launched in 2023. The Directed Issue of SEK 240 million is subject to the approval by an EGM. The net proceeds from the Directed Issue will primarily finance the U.S. Food and Drug Administration (“FDA”) regulatory process for Lucamzi™ and pre-filled syringe development for Ximluci® / Lucamzi™, payment of accumulated accounts payable to suppliers related to Xdivane™, as well as general corporate purposes.

• Onesource Specialty Pharma Limited to subscribe to equity shares of Xbrane Biopharma AB, Sweden
• Xbrane Biopharma AB develops biological drugs using patented platform technology
• Xbrane Biopharma AB portfolio includes biosimilar candidates targeting EUR 23 billion in combined peak annual sales
• Directed Issue of SEK 240 million subject to the approval by an EGM
• Net proceeds from the Directed Issue will primarily finance the FDA regulatory process for Lucamzi™ and pre-filled syringe development for Ximluci® / Lucamzi™, payment of accounts payable related to Xdivane™, and general corporate purposes